Table 3.
N | Events/pyr | Rate/100pyr | Crude HR (95%CI) | Adjusted HR (95%CI) | |
---|---|---|---|---|---|
Overall | 438 | 205/ 631.98 | 32.4 | ||
Study arm | |||||
Placebo | 219 | 110/303.8 | 36.21 | 1.0 | 1.0 |
Treatment | 219 | 95/328.1 | 28.95 | 0.79(0.60, 1.04) | 0.75 (0.57,0.99) |
Sex | |||||
Female | 310 | 143/440.4 | 32.5 | 1.0 | 1.0 |
Male | 128 | 62/191.6 | 32.4 | 0.98 (0.73,1.33) | 0.79 (0.57,1.08) |
Age-group | |||||
20-29 | 90 | 49/126.2 | 38.8 | 1.0 | 1.0 |
30-39 | 185 | 82/267.1 | 30.7 | 0.80 (0.56,1.14) | 0.87 (0.60,1.24) |
40-49 | 107 | 49/162.3 | 30.2 | 0.78 (0.53,1.16) | 0.95 (0.63,1.44) |
50+ | 56 | 25/76.3 | 32.7 | 0.90 (0.56,1.46) | 1.01 (0.62,1.67) |
Baseline CD4 | |||||
300-349 | 211 | 117/282.3 | 25.2 | 1.0 | 1.0 |
350-399 | 227 | 88/349.7 | 41.4 | 0.57 (0.43,0.75) | 0.58 (0.44,0.77) |
Baseline Viral load | |||||
<10 000 | 132 | 37/218.8 | 16.9 | 1.0 | |
10 000-49 999 | 138 | 73/202.1 | 36.1 | 2.25 (1.51,3.34) | 2.20 (1.47,3.29) |
50 000-99 999 | 43 | 27/61.1 | 44.2 | 2.92 (1.77,4.79) | 2.82 (1.70,4.68) |
100 000+ | 125 | 68/149.97 | 45.3 | 3.01 (2.02,4.50) | 3.17 (2.10,4.78) |
Baseline Viral load | |||||
<50 000 | 270 | 110/420.9 | 26.1 | 1.0 | |
50 000+ | 168 | 95/211.1 | 45.0 | 1.88 (1.43,2.48) |
ART: antiretroviral therapy, pyr: person years, HR: hazard ratio